Masitinib
Based on 5 publication(s) in Google Scholar
Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.66%
- CAS. Nr.: 790299-79-5
- Formel: C28H30N6OS
- Molecular Weight:498.64
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-15463
ImatinibTyrosine Kinases Inhibitor -
HY-10159
NilotinibBcr-Abl Inhibitor -
HY-10181
DasatinibSrc/Bcr-Abl Inhibitor -
HY-16561
ResveratrolPolyphenolic Phytoalexin -
HY-101561
AvapritinibKIT/PDGFRA Inhibitor -
HY-10087
NavitoclaxBcl-2 Inhibitor -
HY-16749
PexidartinibCSF1R/c-Kit Inhibitor -
HY-112306
RipretinibKIT/PDGFRA Inhibitor -
HY-10162
OlaparibPARP Inhibitor -
HY-101445
TroloxAntioxidant -
HY-N0197
BaicalinAutophagy Inducer -
HY-N0193
ArtesunateVirus Protease Inhibitor
Publications Citing Use of MedChemExpress (MCE) Masitinib
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
IF
-
WB
-
Histological Imaging/Staining
Biologische Aktivität
Beschreibung
IC50 & Target
IC50: 200 nM (Kit), 540 nM (PDGFRα), 800 nM (PDGFRβ), 510 nM (LynB)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
3.2 μM
Compound: Masitinib
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37659195] |
| BMMC | IC50 |
0.1 μM
Compound: 1
|
Antiproliferative activity against BALB/c mouse BMMC after 48 hrs by MTT assay
Antiproliferative activity against BALB/c mouse BMMC after 48 hrs by MTT assay
|
[PMID: 30078608] |
| Vero C1008 | EC50 |
3.2 μM
Compound: 8
|
Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral replication
Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral replication
|
[PMID: 37244162] |
In Vitro
Masitinib is a competitive inhibitor against ATP at concentrations ≤500 nM. Masitinib also potently inhibits recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrates weak inhibition of Abl and c-Fms. Masitinib more strongly inhibits degranulation, cytokine production, and bone marrow mast cell migration than imatinib. In Ba/F3 cells expressing human wild-type Kit, masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC50 of 150 nM, while the IC50 for inhibition of IL-3-stimulated proliferation is at approximately >10 μM. In Ba/F3 cells expressing PDGFRα, masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC50 of 300 nM. Masitinib also causes inhibition of SCF-stimulated tyrosine phosphorylation of human Kit in mastocytoma cell-lines and BMMC. Masitinib inhibits Kit gain-of-function mutants, including V559D mutant and Δ27 mouse mutant with IC50 of 3 and 5 nM in Ba/F3 cells. Masitinib inhibits the cell proliferation of mastocytoma cell lines including HMC-1α155 and FMA3 with IC50 of 10 and 30 nM, respectively[1]. Masitinib inhibits cell growth and PDGFR phosphorylation in two novel ISS cell lines, which suggest that Masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Masitinib (12.5 mg/kg/d, p.o.) increases overall TTP (time-to-tumor progression) compared with placebo in dogs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 790299-79-5
-
Appearance Solid
-
Molecular Weight 498.64
-
Formel C28H30N6OS
-
Color White to yellow
-
SMILES
O=C(NC1=CC=C(C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
-
Synonyms
AB1010
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Science
2021 Nov 26;374(6571):1099-1106. PMID: 34648371 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Ecotoxicol Environ Saf
Dibutyl phthalate promotes central precocious puberty through primordial follicle activation by downregulating BMP15. [Abstract]2025 Jul 15:300:118460. PMID: 40472697 -
Eur J Pharmacol
Therapeutic effects of masitinib on abnormal mechanoreception in a mouse model of tourniquet-induced extremity ischemia-reperfusion. [Abstract]2021 Nov 15:911:174549. PMID: 34619116
Masitinib purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Nov 15:911:174549. [Abstract]
Protective effects of Mas (Masitinib; 28 mg/kg/day; i.p.; once daily) on mechanoreception during tourniquet/IR were evaluated by paw withdraw threshold at different reperfusion periods in mice. Mas significantly improved paw mechanoreception in the early stages of reperfusion and decreased allodynia at days 14 through 28.
Masitinib purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Nov 15:911:174549. [Abstract]
Nerve fibers and sensory nerve terminals in the skin of mouse paw pads were stained with PGP9.5 and DAPI after Mas (Masitinib; 28 mg/kg/day; i.p.; once daily) treatment in a hind paw tourniquet/IR model. Treatment with Mas significantly mitigated the sensory nerve damage.
Masitinib purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Nov 15:911:174549. [Abstract]
IL-1β and TNFα protein expression in the skin of mouse paw pads was measured by Western blot after Mas treatment (Masitinib; 28 mg/kg/day; i.p.; once daily) in a hind paw tourniquet/IR model. Treatment with Mas markedly reduced the expression of IL-1β and TNFα protein in the skin of paw pads at 7, 14, and 28 days.
Masitinib purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Nov 15:911:174549. [Abstract]
ROS in the dermal papillae of mouse paw pad skin was stained with H2DCFDA and DAPI at days 1 and 3 of reperfusion after Mas treatment (Masitinib; 28 mg/kg/day; i.p.; once daily) in a hind paw tourniquet/IR model. Treatment with Mas significantly reduced the ROS production at 1 and 3 days.
-
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (200.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[2]. Lawrence J, et al. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Vet Comp Oncol, 2011, doi: 10.1111/j.1476-5829.2011.00291.x. [Content Brief]
[3]. Hahn KA, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med, 2008, 22(6), 1301-1309. [Content Brief]
[4]. Marech I, et al. Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol. 2014 Jul;91(1):98-111. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0055 mL | 10.0273 mL | 20.0545 mL | 50.1364 mL |
| 5 mM | 0.4011 mL | 2.0055 mL | 4.0109 mL | 10.0273 mL | |
| 10 mM | 0.2005 mL | 1.0027 mL | 2.0055 mL | 5.0136 mL | |
| 15 mM | 0.1337 mL | 0.6685 mL | 1.3370 mL | 3.3424 mL | |
| 20 mM | 0.1003 mL | 0.5014 mL | 1.0027 mL | 2.5068 mL | |
| 25 mM | 0.0802 mL | 0.4011 mL | 0.8022 mL | 2.0055 mL | |
| 30 mM | 0.0668 mL | 0.3342 mL | 0.6685 mL | 1.6712 mL | |
| 40 mM | 0.0501 mL | 0.2507 mL | 0.5014 mL | 1.2534 mL | |
| 50 mM | 0.0401 mL | 0.2005 mL | 0.4011 mL | 1.0027 mL | |
| 60 mM | 0.0334 mL | 0.1671 mL | 0.3342 mL | 0.8356 mL | |
| 80 mM | 0.0251 mL | 0.1253 mL | 0.2507 mL | 0.6267 mL | |
| 100 mM | 0.0201 mL | 0.1003 mL | 0.2005 mL | 0.5014 mL |
Masitinib Related Classifications
HY-10209 Related Classifications
Powered by Bioz